Cinnamic Acid

Cinnamic Acid

SCHEMBL363486

CC(C)CC(=O)O.O=C(O)C=Cc1ccccc1

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.66
HDAC3 O15379 2/20 0.66
HDAC4 P56524 2/20 0.66
HDAC1 Q13547 2/20 0.66
HDAC2 Q92769 2/20 0.66
HDAC8 Q9BY41 2/20 0.66
HDAC6 Q9UBN7 2/20 0.66
TNKS O95271 1/20 0.66
HDAC7 Q8WUI4 1/20 0.66
HDAC10 Q969S8 1/20 0.66
HDAC11 Q96DB2 1/20 0.66
TNKS2 Q9H2K2 1/20 0.66
HDAC9 Q9UKV0 1/20 0.66
HDAC5 Q9UQL6 1/20 0.66
MAPK1 P28482 2/20 0.54
KDM4E B2RXH2 2/20 0.54
TDP1 Q9NUW8 2/20 0.52
GLA P06280 1/20 0.52
ALDH1A1 P00352 4/20 0.50
PLIN1 O60240 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cinnamic Acid SCHEMBL363485 1.00 HCAR2 (0.66) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL11766944 0.84 HCAR2 (0.68) HCAR2HDAC3HDAC4HDAC1HDAC2
SCHEMBL2124075 0.82 ALDH1A1 (0.58) HCAR2HDAC3HDAC4HDAC1HDAC2
SCHEMBL2124073 0.82 ALDH1A1 (0.58) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL29010568 0.82 HCAR2 (0.76) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL28221403 0.82 HCAR2 (0.76) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL14954771 0.82 HCAR2 (0.76) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL28221402 0.82 HCAR2 (0.76) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL14954770 0.82 HCAR2 (0.76) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL10881703 0.81 HCAR2 (0.91) HCAR2HDAC3HDAC4HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010105922-A1 IMPROVEMENTS RELATING TO BENEFIT AGENT DELIVERY UNILEVER PLC (GB) 2010-09-23 WO claimed
EP-1567629-B1 LAUNDRY TREATMENT COMPOSITIONS AND COMPONENTS THEREFOR UNILEVER PLC (GB) 2007-03-07 EP claimed
CN-106604715-B Use of benefit delivery particles for off-flavour benefits 荷兰联合利华有限公司 2020-04-17 CN disclosed
CN-110461419-A It is provided with the cosmetic preparation of mesh CHANEL PARFUMS BEAUTE 2019-11-15 CN disclosed
EP-2911643-B1 IMPROVEMENTS RELATING TO ENCAPSULATED BENEFIT AGENTS UNILEVER PLC (GB) 2018-12-05 EP disclosed
US-10117815-B2 Improvements relating to encapsulated benefit agents CONOPCO, INC. (US) 2018-11-06 US disclosed
US-10034818-B2 Use of a benefit delivery particle for malodour benefit CONOPCO, INC. (US) 2018-07-31 US disclosed
EP-3148650-B1 BENEFIT DELIVERY PARTICLE FOR TREATING SUBSTRATES UNILEVER PLC (GB) 2018-07-04 EP disclosed
US-9993401-B2 Benefit delivery particle, process for preparing said particle, compositions comprising said particles and a method for treating substrates CONOPCO, INC. (US) 2018-06-12 US disclosed
EP-1442109-B1 POLYMERS FOR LAUNDRY APPLICATIONS UNILEVER PLC (GB) 2018-04-25 EP disclosed
EP-3148649-B1 USE OF PARTICLES TO ABSORB MALODORS UNILEVER PLC (GB) 2017-11-29 EP disclosed
US-20030068495-A1 Treatment for substrates UNILEVER HOME & PERSONAL CARE USA 2003-04-10 US disclosed
WO-2003020770-A1 POLYMERS AND THEIR USE UNILEVER PLC (GB) 2003-03-13 WO disclosed
WO-2003020819-A1 LAUNDRY TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2003-03-13 WO disclosed
WO-2003014278-A1 TREATMENT FOR SUBSTRATES UNILEVER PLC (GB) 2003-02-20 WO disclosed
WO-2003010267-A1 USE OF POLYMERS IN FABRICS CLEANING UNILEVER PLC (GB) 2003-02-06 WO disclosed
WO-2003010268-A1 USE OF COMPOUNDS IN PRODUCTS FOR LAUNDRY APPLICATIONS UNILEVER PLC (GB) 2003-02-06 WO disclosed
WO-2003010206-A1 POLYMERS AND THEIR SYNTHESIS UNILEVER PLC (GB) 2003-02-06 WO disclosed
EP-1117755-A1 TREATMENT FOR SUBSTRATES UNILEVER PLC (GB) 2001-07-25 EP disclosed
WO-2000018861-A1 TREATMENT FOR SUBSTRATES UNILEVER PLC (GB) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10117815-B2 Improvements relating to encapsulated benefit agents CD44, HSPA2, HSPA1A HCAR2 1685/4885HDAC3 1059/4885HDAC4 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.